Aspirin Reveals ‘Huge Effect’ in Reducing Colorectal Cancer Return, Research Reports

A daily amount of aspirin can dramatically lower the risk of certain bowel cancers returning after operation, based on a major trial into the preventive effects of the everyday drug.

Swedish researchers found that patients who used a modest regular amount of aspirin after having cancer surgery were twice as less likely to have a cancer relapse over the subsequent three years compared to those who were given a placebo.

The trial included cancer patients whose cancers carried certain DNA alterations that rendered them susceptible to its cancer-fighting qualities. Roughly two-fifths of bowel cancer sufferers possess similar alterations.

“I believe this will alter clinical practice,” commented one expert. “If you had such genetic profiles, the risk of the cancer returning was decreased by above 50%. It is a substantial effect.”

Almost millions of individuals are identified with bowel cancer every year around the world, with over thousands of cases in the United Kingdom. Many undergo cancer excision, but in spite of improvements in chemo, beam therapy and surgery, the malignancy can come back if cells are not fully removed.

Incidence of bowel cancer are increasing across the globe in people under 50, and while the causes are unknown, researchers suspect that junk food, being overweight, a lack of physical activity and chemicals generated by gut bacteria are implicated.

Earlier trials have indicated that the drug can help stop bowel cancer in individuals who are at high risk due to genetic disorders such as Lynch syndrome. However, it was unclear whether the medication lowered the likelihood of malignancy coming back after an operation.

Scientists enrolled above 3,500 patients who had undergone intestinal tumor removal at medical centers across several countries. Genetic screening on 2,980 of the patients identified over 1,100, or more than a third, had alterations in genes that are part of a cellular process referred to as a gene pathway, which is involved in the disease.

The individuals with the mutations were divided to take either 160mg of medication per day or a placebo for three years after surgery. Those taking the active drug were significantly at lower risk to see the cancer return than those on the inactive treatment, the study demonstrated.

The treatment is believed to shield against the disease by dampening swelling, interacting with the PI3K pathway, and limiting the behavior of blood platelets, which can protect malignant cells and potentially hide them from the body’s immune system.

Experts emphasized the necessity to conduct molecular analysis on every colorectal cancers so that people who might benefit from this approach could be offered the therapy. “This is a common medication that is very low-cost,” they noted.

The drug has been available for over a century, but consuming the treatment long-term still carries potential side effects. In the study, several participants experienced “severe reactions” potentially related to the treatment, such as hypersensitivity, stomach bleeding and bleeding on the brain. A few participants succumbed across both sides of the research, with a single loss potentially attributed by aspirin.

A research director commented: “Preventing cancer diagnoses preserves life, and identifying new ways to achieve this is key to ongoing work to beat cancer. There is increasing proof that in specific individuals of individuals, low-dose aspirin can provide defense from bowel cancer.”

“We need larger, rigorous trials to verify which individuals would most benefit from consuming the medication to help them live longer, improved quality of life, free from the anxiety of malignancy.”